Advanced

Mutations of PTEN gene in gliomas correlate to tumor differentiation and short-term survival rate.

Yang, Yiling; Shao, Naiyuan; Luo, Guanghua; Li, Lu; Zheng, Lu; Nilsson-Ehle, Peter LU and Xu, Ning LU (2010) In Anticancer Research 30(3). p.981-985
Abstract
The present study determined mutations of phosphatase and tensin homolog (PTEN) gene in patients suffering from high-grade gliomas (WHO grades III and IV) and further investigated the mutations in correlation to patients' histopathological classification and short-term survival. Total RNA and genomic DNA were extracted from tumor tissues. Full-length PTEN cDNA sequences were amplified by polymerase chain reaction (PCR). The PCR products were directly sequenced, and the PTEN mutations were analyzed. It demonstrated that the incidence of PTEN mutations was 8/22 in these patients: one patient with WHO grade III glioma (1/11) and 7 patients with WHO grade IV glioma (7/11). Most patients had three or more mutations in the PTEN gene, with exons... (More)
The present study determined mutations of phosphatase and tensin homolog (PTEN) gene in patients suffering from high-grade gliomas (WHO grades III and IV) and further investigated the mutations in correlation to patients' histopathological classification and short-term survival. Total RNA and genomic DNA were extracted from tumor tissues. Full-length PTEN cDNA sequences were amplified by polymerase chain reaction (PCR). The PCR products were directly sequenced, and the PTEN mutations were analyzed. It demonstrated that the incidence of PTEN mutations was 8/22 in these patients: one patient with WHO grade III glioma (1/11) and 7 patients with WHO grade IV glioma (7/11). Most patients had three or more mutations in the PTEN gene, with exons 2, 3, 4, 5, 6 and 7 as hot mutation regions, with mutation incidence from 62.5% to 75%. About 68.4% of mutations were missense, 26.3% same-sense and 5.3% nonsense mutations. The median survival times of the WHO grade III and IV groups were 250 and 53 weeks after surgery, respectively (p=0.016). The 36-week survival rate of patients with and without PTEN mutations was 62.5% and 92.9% (p=0.038, odds ratio=7.80), respectively. The present study suggests that PTEN mutations are late events in the malignant progression of glioma and the occurrence of PTEN mutations are significantly correlated to patients' short-term survival. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Anticancer Research
volume
30
issue
3
pages
981 - 985
publisher
International Institute of Cancer Research
external identifiers
  • wos:000276561300038
  • pmid:20393024
  • scopus:77951063125
ISSN
1791-7530
language
English
LU publication?
yes
id
2bbc799f-d08a-4092-b081-565f5a7ad9bf (old id 1595293)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/20393024?dopt=Abstract
date added to LUP
2010-05-04 22:05:39
date last changed
2018-07-15 04:19:30
@article{2bbc799f-d08a-4092-b081-565f5a7ad9bf,
  abstract     = {The present study determined mutations of phosphatase and tensin homolog (PTEN) gene in patients suffering from high-grade gliomas (WHO grades III and IV) and further investigated the mutations in correlation to patients' histopathological classification and short-term survival. Total RNA and genomic DNA were extracted from tumor tissues. Full-length PTEN cDNA sequences were amplified by polymerase chain reaction (PCR). The PCR products were directly sequenced, and the PTEN mutations were analyzed. It demonstrated that the incidence of PTEN mutations was 8/22 in these patients: one patient with WHO grade III glioma (1/11) and 7 patients with WHO grade IV glioma (7/11). Most patients had three or more mutations in the PTEN gene, with exons 2, 3, 4, 5, 6 and 7 as hot mutation regions, with mutation incidence from 62.5% to 75%. About 68.4% of mutations were missense, 26.3% same-sense and 5.3% nonsense mutations. The median survival times of the WHO grade III and IV groups were 250 and 53 weeks after surgery, respectively (p=0.016). The 36-week survival rate of patients with and without PTEN mutations was 62.5% and 92.9% (p=0.038, odds ratio=7.80), respectively. The present study suggests that PTEN mutations are late events in the malignant progression of glioma and the occurrence of PTEN mutations are significantly correlated to patients' short-term survival.},
  author       = {Yang, Yiling and Shao, Naiyuan and Luo, Guanghua and Li, Lu and Zheng, Lu and Nilsson-Ehle, Peter and Xu, Ning},
  issn         = {1791-7530},
  language     = {eng},
  number       = {3},
  pages        = {981--985},
  publisher    = {International Institute of Cancer Research},
  series       = {Anticancer Research},
  title        = {Mutations of PTEN gene in gliomas correlate to tumor differentiation and short-term survival rate.},
  volume       = {30},
  year         = {2010},
}